Explore

Trendline Trendline
Pfizer and Innovent Biologics Announce $10.5 Billion Cancer Treatment Collaboration

Pfizer and Innovent Biologics Announce $10.5 Billion Cancer Treatment Collaboration

Pfizer and Innovent Biologics Announce $10.5 Billion Cancer Treatment Collaboration
Trendline Trendline
Pfizer and Innovent Biologics Collaborate to Advance Oncology Medicines Globally

Pfizer and Innovent Biologics Collaborate to Advance Oncology Medicines Globally

Pfizer and Innovent Biologics Collaborate to Advance Oncology Medicines Globally
Trendline Trendline
Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets

Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets

Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets
Trendline Trendline
Pfizer and Innovent Biologics Forge $10.5 Billion Cancer Research Alliance

Pfizer and Innovent Biologics Forge $10.5 Billion Cancer Research Alliance

Pfizer and Innovent Biologics Forge $10.5 Billion Cancer Research Alliance
Trendline Trendline
Innovent Biologics Shares Surge After $10.5 Billion Deal with Pfizer

Innovent Biologics Shares Surge After $10.5 Billion Deal with Pfizer

Innovent Biologics Shares Surge After $10.5 Billion Deal with Pfizer
Trendline Trendline
Pfizer and Innovent Biologics Forge $10.5 Billion Oncology Partnership, Boosting Innovent Shares

Pfizer and Innovent Biologics Forge $10.5 Billion Oncology Partnership, Boosting Innovent Shares

Pfizer and Innovent Biologics Forge $10.5 Billion Oncology Partnership, Boosting Innovent Shares
Trendline Trendline
Pfizer and Innovent Biologics Partner in $10.5 Billion Cancer Therapy Deal

Pfizer and Innovent Biologics Partner in $10.5 Billion Cancer Therapy Deal

Pfizer and Innovent Biologics Partner in $10.5 Billion Cancer Therapy Deal
Trendline Trendline
Exelixis to Present at Major Healthcare Conferences, Highlighting Oncology Innovations

Exelixis to Present at Major Healthcare Conferences, Highlighting Oncology Innovations

Exelixis to Present at Major Healthcare Conferences, Highlighting Oncology Innovations
Trendline Trendline
Bristol Myers Squibb's Mezigdomide Shows Significant Efficacy in Multiple Myeloma Treatment

Bristol Myers Squibb's Mezigdomide Shows Significant Efficacy in Multiple Myeloma Treatment

Bristol Myers Squibb's Mezigdomide Shows Significant Efficacy in Multiple Myeloma Treatment
Trendline Trendline
Verastem Oncology to Present at Jefferies Healthcare Conference 2026

Verastem Oncology to Present at Jefferies Healthcare Conference 2026

Verastem Oncology to Present at Jefferies Healthcare Conference 2026
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies